Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ionis Subsidiary Akcea Encouraged By Safety Data In FCS

Executive Summary

Phase III data showing statistically significant reduction of triglycerides will bolster the pivotal data expected early next year. Akcea is not concerned by the study’s 20% dropout rate because there were no discontinuations in a subset of patients with FCS.

You may also be interested in...



Akcea Faces Tricky Risk/Benefit Scenario In Orphan Disease FCS

The Ionis subsidiary's volanesorsen shows robust efficacy in a pivotal Phase III trial for familial chylomicronemia syndrome, but with high dropout levels for platelet reduction. Firm says platelet reductions are manageable and stem from the drug working as expected in the rare disease.

Ionis: Another Shot At The Commercial Market And Sustainable Profits

Spinraza, launched by partner Biogen, is the antisense developer’s newest drug to reach the market. Ionis plans to file its first wholly-owned drug, volanesorsen, later this year.

Isis antisense drug lowers triglycerides; Phase III ongoing

Isis Pharmaceuticals has one Phase III clinical trial under way with a second late-stage trial expected to start before the end of 2015 for its antisense drug volanesorsen (ISIS-APOCIIIRx), which was able to significantly lower patients' triglyceride levels in a Phase II study.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC097911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel